<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36144420</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-2607</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>11</Day></PubDate></JournalIssue><Title>Microorganisms</Title><ISOAbbreviation>Microorganisms</ISOAbbreviation></Journal><ArticleTitle>The Effect of Anaerobically Cultivated Human Intestinal Microbiota Compared to Fecal Microbiota Transplantation on Gut Microbiota Profile and Symptoms of Irritable Bowel Syndrome, a Double-Blind Placebo-Controlled Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1819</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/microorganisms10091819</ELocationID><Abstract><AbstractText>Fecal microbiota transplantation (FMT) from healthy donors has been shown to improve the symptoms of irritable bowel syndrome (IBS) and changes the profile of the gut microbiota for the recipients. Alternatively, anaerobically cultivated human intestinal microbiota (ACHIM) can be used to manipulate the gut microbiota. The aim of the current study was to compare the efficacy and safety of ACHIM suspension with donor-FMT and placebo (patient's own feces) to treat IBS. Out of the 62 originally included eligible patients with diarrhea-predominant IBS and their respective donors, only 43 patients completed the study by answering the questionnaires and delivering fecal samples before transplantation and after 1, 4, 12 and 24 weeks. The patients were randomized into three subgroups for receiving ACHIM suspension (<i>n</i> = 17), donor-FMT (<i>n</i> = 11), or placebo (<i>n</i> = 15), and were followed up for 24 weeks. Fecal samples were analyzed by sequencing 16S rRNA gene using the GA-map Dysbiosis Test (Genetic Analysis AS, Oslo, Norway). IBS symptom questionnaires improved in all three subgroups. Bacterial strain signals in IBS patients were more significant for <i>Actinobacteria</i> spp. and <i>Bifidobacteria</i> spp. after receiving donor-FMT compared to placebo and for <i>Alistipes onderdonkii</i> before and after treatment in the subgroups of ACHIM and donor-FMT vs. placebo. These signals change after treatment with ACHIM suspension and donor FMT towards those measured for healthy controls, but not after placebo. IBS symptom questionnaires improved in all three forms of transplantation. Some bacterial strain signals were significantly different between ACHIM and donor-FMT vs. placebo. However, the placebo subgroup failed to change the gut microbiota towards signals measured for healthy controls. The safety and efficacy of ACHIM and donor-FMT seems similar in the current study, but further larger studies are needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mazzawi</LastName><ForeName>Tarek</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7983-3707</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Norwegian Competence Center for Functional Gastrointestinal Disorders, Section of Gastroenterology, Haukeland University Hospital, 5021 Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Nutrition, Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Al-Balqa Applied University, 19117 Al-Salt, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hausken</LastName><ForeName>Trygve</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7080-8396</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Norwegian Competence Center for Functional Gastrointestinal Disorders, Section of Gastroenterology, Haukeland University Hospital, 5021 Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Nutrition, Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Refsnes</LastName><ForeName>Per F&#xf8;rde</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Norwegian Competence Center for Functional Gastrointestinal Disorders, Section of Gastroenterology, Haukeland University Hospital, 5021 Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Nutrition, Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatlebakk</LastName><ForeName>Jan Gunnar</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Norwegian Competence Center for Functional Gastrointestinal Disorders, Section of Gastroenterology, Haukeland University Hospital, 5021 Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Nutrition, Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lied</LastName><ForeName>G&#xfc;len Arslan</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Norwegian Competence Center for Functional Gastrointestinal Disorders, Section of Gastroenterology, Haukeland University Hospital, 5021 Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Nutrition, Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F-10463/4800001918</GrantID><Agency>Western Norway Regional Health Authority</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Microorganisms</MedlineTA><NlmUniqueID>101625893</NlmUniqueID><ISSNLinking>2076-2607</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">16S rRNA sequencing</Keyword><Keyword MajorTopicYN="N">ACHIM</Keyword><Keyword MajorTopicYN="N">FMT</Keyword><Keyword MajorTopicYN="N">IBS</Keyword><Keyword MajorTopicYN="N">gut microbiota</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>1</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36144420</ArticleId><ArticleId IdType="pmc">PMC9503104</ArticleId><ArticleId IdType="doi">10.3390/microorganisms10091819</ArticleId><ArticleId IdType="pii">microorganisms10091819</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Oka P., Parr H., Barberio B., Black C.J., Savarino E.V., Ford A.C. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2020;5:908&#x2013;917. doi: 10.1016/S2468-1253(20)30217-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30217-X</ArticleId><ArticleId IdType="pubmed">32702295</ArticleId></ArticleIdList></Reference><Reference><Citation>Talley N.J., Gabriel S.E., Harmsen W., Zinsmeister A.R., Evans R.W. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology. 1995;109:1736&#x2013;1741. doi: 10.1016/0016-5085(95)90738-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0016-5085(95)90738-6</ArticleId><ArticleId IdType="pubmed">7498636</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandler R.S., Everhart J.E., Donowitz M., Adams E., Cronin K., Goodman C., Gemmen E., Shah S., Avdic A., Rubin R. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500&#x2013;1511. doi: 10.1053/gast.2002.32978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/gast.2002.32978</ArticleId><ArticleId IdType="pubmed">11984534</ArticleId></ArticleIdList></Reference><Reference><Citation>Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C. Functional Bowel Disorders. Gastroenterology. 2006;130:1480&#x2013;1491. doi: 10.1053/j.gastro.2005.11.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2005.11.061</ArticleId><ArticleId IdType="pubmed">16678561</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M., Gundersen D., Hatlebakk J.G., Hausken T. Irritable Bowel Syndrome. Nova Science Publisher; New York, NY, USA: 2012.</Citation></Reference><Reference><Citation>El-Salhy M., Hatlebakk J.G., Gilja O.H., Hausken T. Irritable bowel syndrome: Recent developments in diagnosis, pathophysiology, and treatment. Expert Rev. Gastroenterol. Hepatol. 2014;8:435&#x2013;443. doi: 10.1586/17474124.2014.888952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/17474124.2014.888952</ArticleId><ArticleId IdType="pubmed">24580043</ArticleId></ArticleIdList></Reference><Reference><Citation>Codling C., O&#x2019;Mahony L., Shanahan F., Quigley E.M.M., Marchesi J.R. A Molecular Analysis of Fecal and Mucosal Bacterial Communities in Irritable Bowel Syndrome. Am. J. Dig. Dis. 2009;55:392&#x2013;397. doi: 10.1007/s10620-009-0934-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-009-0934-x</ArticleId><ArticleId IdType="pubmed">19693670</ArticleId></ArticleIdList></Reference><Reference><Citation>Tana C., Umesaki Y., Imaoka A., Handa T., Kanazawa M., Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol. Motil. 2009;22:512-e115. doi: 10.1111/j.1365-2982.2009.01427.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2009.01427.x</ArticleId><ArticleId IdType="pubmed">19903265</ArticleId></ArticleIdList></Reference><Reference><Citation>Whorwell P., Altringer L., Morel J., Bond Y., Charbonneau D., O&#x2019;Mahony L., Kiely B., Shanahan F., Quigley E.M.M. Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome. Am. J. Gastroenterol. 2006;101:1581&#x2013;1590. doi: 10.1111/j.1572-0241.2006.00734.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00734.x</ArticleId><ArticleId IdType="pubmed">16863564</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisson G., Ayis S., Sherwood R.A., Bjarnason I. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome&#x2014;A 12 week double-blind study. Aliment. Pharmacol. Ther. 2014;40:51&#x2013;62. doi: 10.1111/apt.12787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12787</ArticleId><ArticleId IdType="pubmed">24815298</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsson F., F&#xe5;k F., Nookaew I., Tremaroli V., Fagerberg B., Petranovic D., B&#xe4;ckhed F., Nielsen J. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat. Commun. 2012;3:1245. doi: 10.1038/ncomms2266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2266</ArticleId><ArticleId IdType="pmc">PMC3538954</ArticleId><ArticleId IdType="pubmed">23212374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ley R.E., Turnbaugh P.J., Klein S., Gordon J.I. Human Gut Microbes Associated with Obesity. Nature. 2006;444:1022&#x2013;1023. doi: 10.1038/4441022a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/4441022a</ArticleId><ArticleId IdType="pubmed">17183309</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzawi T., Hausken T., Hov J.R., Valeur J., Sangnes D.A., El-Salhy M., Gilja O.H., Hatlebakk J.G., Lied G.A. Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels. Scand. J. Gastroenterol. 2019;54:690&#x2013;699. doi: 10.1080/00365521.2019.1624815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365521.2019.1624815</ArticleId><ArticleId IdType="pubmed">31190584</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzawi T., Lied G.A., Sangnes D.A., El-Salhy M., Hov J.R., Gilja O.H., Hatlebakk J.G., Hausken T. The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation. PLoS ONE. 2018;13:e0194904. doi: 10.1371/journal.pone.0194904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0194904</ArticleId><ArticleId IdType="pmc">PMC6235238</ArticleId><ArticleId IdType="pubmed">30427836</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow J.R., Davis S.L., Chaykosky D.M., Smith T.T., Smith J.M. Probiotics and Fecal Microbiota Transplant for Primary and Secondary Prevention of Clostridium difficile Infection. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2015;35:1016&#x2013;1025. doi: 10.1002/phar.1644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/phar.1644</ArticleId><ArticleId IdType="pubmed">26598094</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt L.J. American Journal of Gastroenterology Lecture: Intestinal Microbiota and the Role of Fecal Microbiota Transplant (FMT) in Treatment of C. difficile Infection. Am. J. Gastroenterol. 2013;108:177&#x2013;185. doi: 10.1038/ajg.2012.450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2012.450</ArticleId><ArticleId IdType="pubmed">23318479</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt L.J., Aroniadis O.C., Mellow M., Kanatzar A., Kelly C., Park T., Stollman N., Rohlke F., Surawicz C. Long-Term Follow-Up of Colonoscopic Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection. Am. J. Gastroenterol. 2012;107:1079&#x2013;1087. doi: 10.1038/ajg.2012.60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2012.60</ArticleId><ArticleId IdType="pubmed">22450732</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunde S., Pham A., Bonczyk S., Crumb T., Duba M., Conrad H., Cloney D., Kugathasan S. Safety, Tolerability, and Clinical Response After Fecal Transplantation in Children and Young Adults With Ulcerative Colitis. J. Pediatr. Gastroenterol. Nutr. 2013;56:597&#x2013;601. doi: 10.1097/MPG.0b013e318292fa0d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0b013e318292fa0d</ArticleId><ArticleId IdType="pubmed">23542823</ArticleId></ArticleIdList></Reference><Reference><Citation>Cammarota G., Ianiro G., Tilg H., Rajili&#x107;-Stojanovi&#x107; M., Kump P., Satokari R., Sokol H., Arkkila P., Pintus C., Hart A., et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66:569&#x2013;580. doi: 10.1136/gutjnl-2016-313017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2016-313017</ArticleId><ArticleId IdType="pmc">PMC5529972</ArticleId><ArticleId IdType="pubmed">28087657</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnsen P.H., Hilp&#xfc;sch F., Cavanagh J.P., Leikanger I.S., Kolstad C., Valle P.C., Goll R. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: A double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol. Hepatol. 2018;3:17&#x2013;24. doi: 10.1016/S2468-1253(17)30338-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(17)30338-2</ArticleId><ArticleId IdType="pubmed">29100842</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M., Hatlebakk J.G., Gilja O.H., Kristoffersen A.B., Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2019;69:859&#x2013;867. doi: 10.1136/gutjnl-2019-319630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2019-319630</ArticleId><ArticleId IdType="pmc">PMC7229896</ArticleId><ArticleId IdType="pubmed">31852769</ArticleId></ArticleIdList></Reference><Reference><Citation>Benno P., Norin E., Midtvedt T., Hellstr&#xf6;m P. Therapeutic potential of an anaerobic cultured human intestinal microbiota, ACHIM, for treatment of IBS. Best Pr. Res. Clin. Gastroenterol. 2019;40-41:101607. doi: 10.1016/j.bpg.2019.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpg.2019.03.003</ArticleId><ArticleId IdType="pubmed">31594647</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafsson A., Berstad A., Lund-Tonnesen S., Midtvedt T., Norin E. The effect of faecal enema on five microflora-associated characteristics in patients with antibiotic-associated diarrhoea. Scand. J. Gastroenterol. 1999;34:580&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pubmed">10440607</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianiro G., Mullish B.H., Kelly C.R., Sokol H., Kassam Z., Ng S.C., Fischer M., Allegretti J.R., Masucci L., Zhang F., et al. Screening of faecal microbiota transplant donors during the COVID-19 outbreak: Suggestions for urgent updates from an international expert panel. Lancet Gastroenterol. Hepatol. 2020;5:430&#x2013;432. doi: 10.1016/S2468-1253(20)30082-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30082-0</ArticleId><ArticleId IdType="pmc">PMC7104244</ArticleId><ArticleId IdType="pubmed">32192627</ArticleId></ArticleIdList></Reference><Reference><Citation>Juul F.E., Garborg K., Bretthauer M., Skudal H., &#xd8;ines M.N., Wiig H., Rose &#xd8;., Seip B., Lamont J.T., Midtvedt T., et al. Fecal Microbiota Transplantation for Primary Clostridium difficile Infection. N. Engl. J. Med. 2018;378:2535&#x2013;2536. doi: 10.1056/NEJMc1803103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1803103</ArticleId><ArticleId IdType="pubmed">29860912</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann-Vold A.-M., Fretheim H.H., Sarna V.K., Barua I., Carstens M.N., Distler O., Khanna D., Volkmann E.R., Midtvedt &#xd8;., Didriksen H., et al. Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: Study protocol for the randomised controlled phase II ReSScue trial. BMJ Open. 2021;11:e048541. doi: 10.1136/bmjopen-2020-048541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-048541</ArticleId><ArticleId IdType="pmc">PMC8231046</ArticleId><ArticleId IdType="pubmed">34168032</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association Declaration of Helsinki Ethical principles for medical research involving human subjects. J. Am. Coll. Dent. 2014;81:14&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">25951678</ArticleId></ArticleIdList></Reference><Reference><Citation>Aroniadis O.C., Brandt L.J. Fecal microbiota transplantation. Curr. Opin. Gastroenterol. 2013;29:79&#x2013;84. doi: 10.1097/MOG.0b013e32835a4b3e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOG.0b013e32835a4b3e</ArticleId><ArticleId IdType="pubmed">23041678</ArticleId></ArticleIdList></Reference><Reference><Citation>Cammarota G., Ianiro G., Gasbarrini A. Fecal Microbiota Transplantation for the Treatment of Clostridium difficile Infection. J. Clin. Gastroenterol. 2014;48:693&#x2013;702. doi: 10.1097/MCG.0000000000000046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0000000000000046</ArticleId><ArticleId IdType="pubmed">24440934</ArticleId></ArticleIdList></Reference><Reference><Citation>Cas&#xe9;n C., Veb&#xf8; H.C., Sekelja M., Hegge F.T., Karlsson M.K., Ciemniejewska E., Dzankovic S., Fr&#xf8;yland C.J., Nestestog R., Engstrand L., et al. Deviations in human gut microbiota: A novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment. Pharmacol. Ther. 2015;42:71&#x2013;83. doi: 10.1111/apt.13236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.13236</ArticleId><ArticleId IdType="pmc">PMC5029765</ArticleId><ArticleId IdType="pubmed">25973666</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis C.Y., Morris J., Whorwell P. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 1997;11:395&#x2013;402. doi: 10.1046/j.1365-2036.1997.142318000.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1997.142318000.x</ArticleId><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Arslan G., Lind R., Olafsson S., Florvaag E., Berstad A. Quality of Life in Patients with Subjective Food Hypersensitivity: Applicability of the 10-Item Short Form of the Nepean Dyspepsia Index. Am. J. Dig. Dis. 2004;49:680&#x2013;687. doi: 10.1023/B:DDAS.0000026318.81635.3b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:DDAS.0000026318.81635.3b</ArticleId><ArticleId IdType="pubmed">15185878</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis S.J., Heaton K.W. Stool Form Scale as a Useful Guide to Intestinal Transit Time. Scand. J. Gastroenterol. 1997;32:920&#x2013;924. doi: 10.3109/00365529709011203.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365529709011203</ArticleId><ArticleId IdType="pubmed">9299672</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaton K.W., Radvan J., Cripps H., A Mountford R., E Braddon F., O Hughes A. Defecation frequency and timing, and stool form in the general population: A prospective study. Gut. 1992;33:818&#x2013;824. doi: 10.1136/gut.33.6.818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.33.6.818</ArticleId><ArticleId IdType="pmc">PMC1379343</ArticleId><ArticleId IdType="pubmed">1624166</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickford R.W., Eysenck H.J., Notcutt B. The Structure of Human Personality. Br. J. Sociol. 1954;5:183. doi: 10.2307/587675.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/587675</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen A.R., Engsbro A.L., Bytzer P. Screening instruments for anxiety and depression in patients with irritable bowel syndrome are ambiguous. Dan. Med. J. 2014;61:A4785.</Citation><ArticleIdList><ArticleId IdType="pubmed">24495890</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugaya N., Nomura S., Shimada H. Relationship Between Cognitive Factors and Anxiety in Individuals with Irritable Bowel Syndrome. Int. J. Behav. Med. 2011;19:308&#x2013;315. doi: 10.1007/s12529-011-9195-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12529-011-9195-0</ArticleId><ArticleId IdType="pubmed">21935740</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen A.Y., Jonkers D.M., Leue C., van der Veek P.P., Vidakovic-Vukic M., van Rood Y.R., Clemens C.H., Masclee A.A. Dysfunctional Cognitions, Anxiety and Depression in Irritable Bowel Syndrome. J. Clin. Gastroenterol. 2010;44:e236&#x2013;e241. doi: 10.1097/MCG.0b013e3181eed5d8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e3181eed5d8</ArticleId><ArticleId IdType="pubmed">20733511</ArticleId></ArticleIdList></Reference><Reference><Citation>Holvoet T., Joossens M., Wang J., Boelens J., Verhasselt B., Laukens D., van Vlierberghe H., Hindryckx P., de Vos M., de Looze D., et al. Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating. Gut. 2016;66:980&#x2013;982. doi: 10.1136/gutjnl-2016-312513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2016-312513</ArticleId><ArticleId IdType="pmc">PMC5531219</ArticleId><ArticleId IdType="pubmed">27511198</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennet S.M., Ohman L., Simren M. Gut Microbiota as Potential Orchestrators of Irritable Bowel Syndrome. Gut Liver. 2015;9:318&#x2013;331. doi: 10.5009/gnl14344.</Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl14344</ArticleId><ArticleId IdType="pmc">PMC4413965</ArticleId><ArticleId IdType="pubmed">25918261</ArticleId></ArticleIdList></Reference><Reference><Citation>Duboc H., Rainteau D., Rajca S., Humbert L., Farabos D., Maubert M., Grondin V., Jouet P., Bouhassira D., Seksik P., et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol. Motil. 2012;24:513-e247. doi: 10.1111/j.1365-2982.2012.01893.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2012.01893.x</ArticleId><ArticleId IdType="pubmed">22356587</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassinen A., Krogius-Kurikka L., M&#xe4;kivuokko H., Rinttil&#xe4; T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A. The Fecal Microbiota of Irritable Bowel Syndrome Patients Differs Significantly From That of Healthy Subjects. Gastroenterology. 2007;133:24&#x2013;33. doi: 10.1053/j.gastro.2007.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2007.04.005</ArticleId><ArticleId IdType="pubmed">17631127</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M., Mazzawi T., Hausken T., Hatlebakk J.G. Irritable bowel syndrome patients who are not likely to respond to fecal microbiota transplantation. Neurogastroenterol. Motil. 2022;34:e14353. doi: 10.1111/nmo.14353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.14353</ArticleId><ArticleId IdType="pmc">PMC9539588</ArticleId><ArticleId IdType="pubmed">35302268</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Sung C.Y.J., Lee N., Ni Y., Pihlajam&#xe4;ki J., Panagiotou G., El-Nezami H. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc. Natl. Acad. Sci. USA. 2016;113:E1306&#x2013;E1315. doi: 10.1073/pnas.1518189113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1518189113</ArticleId><ArticleId IdType="pmc">PMC4780612</ArticleId><ArticleId IdType="pubmed">26884164</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalton A., Mermier C., Zuhl M. Exercise influence on the microbiome&#x2013;gut&#x2013;brain axis. Gut Microbes. 2019;10:555&#x2013;568. doi: 10.1080/19490976.2018.1562268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2018.1562268</ArticleId><ArticleId IdType="pmc">PMC6748614</ArticleId><ArticleId IdType="pubmed">30704343</ArticleId></ArticleIdList></Reference><Reference><Citation>Halkj&#xe6;r S.I., Christensen A.H., Lo B.Z.S., Browne P., G&#xfc;nther S., Hansen L.H., Petersen A.M. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: Results from a randomised, double-blind placebo-controlled study. Gut. 2018;67:2107&#x2013;2115. doi: 10.1136/gutjnl-2018-316434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2018-316434</ArticleId><ArticleId IdType="pubmed">29980607</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurokawa S., Kishimoto T., Mizuno S., Masaoka T., Naganuma M., Liang K.-C., Kitazawa M., Nakashima M., Shindo C., Suda W., et al. The effect of fecal microbiota transplantation on psychiatric symptoms among patients with irritable bowel syndrome, functional diarrhea and functional constipation: An open-label observational study. J. Affect. Disord. 2018;235:506&#x2013;512. doi: 10.1016/j.jad.2018.04.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2018.04.038</ArticleId><ArticleId IdType="pubmed">29684865</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>